[Risk of gastrointestinal bleeding with aspirin and platelet antiaggregants].

  • 12


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Aspirin is widely used for the prevention of thrombotic cardiovascular disease. The effect of platelet antiaggregation is achieved with low doses of 75-325 mg/day. Due to COX-1 inhibition, associated gastrointestinal adverse effects can occur. Other drugs whose platelet antiaggregant effect is achieved through different mechanisms of action have been developed, such as clopidogrel and ticlopidine, which do not inhibit COX-1. The proportion of patients taking low-dose aspirin alone or in combination with other antiaggregants is high and consequently the use of these drugs should be optimized by reducing their gastrointestinal adverse effects to a minimum. Knowledge of the risk factors that increase the risk of gastrointestinal adverse effects with platelet antiaggregants, such as age, concomitant use of other drugs such as anticoagulants or non-steroidal anti-inflammatory drugs, a history of peptic ulcer -whether complicated or uncomplicated-, and Helicobacter pylori infection, would help to allow management to be individually tailored to each patient. The use of proton pump inhibitors and/or H. pylori eradication should allow a positive balance, even in patients with gastrointestinal risk factors.

Author-supplied keywords

  • 80 and over
  • Age Factors
  • Aged
  • Anti-Bacterial Agents
  • Anti-Bacterial Agents: pharmacology
  • Anti-Bacterial Agents: therapeutic use
  • Anti-Inflammatory Agents
  • Anticoagulants
  • Anticoagulants: adverse effects
  • Anticoagulants: therapeutic use
  • Aspirin
  • Aspirin: administration & dosage
  • Aspirin: adverse effects
  • Aspirin: pharmacology
  • Cyclooxygenase 1
  • Cyclooxygenase 1: drug effects
  • Cyclooxygenase Inhibitors
  • Cyclooxygenase Inhibitors: adverse effects
  • Dinoprostone
  • Dinoprostone: physiology
  • Gastrointestinal Hemorrhage
  • Gastrointestinal Hemorrhage: chemically induced
  • Helicobacter Infections
  • Helicobacter Infections: complications
  • Helicobacter Infections: drug therapy
  • Helicobacter pylori
  • Helicobacter pylori: drug effects
  • Histamine H2 Antagonists
  • Histamine H2 Antagonists: therapeutic use
  • Humans
  • Middle Aged
  • Misoprostol
  • Misoprostol: therapeutic use
  • Non-Steroidal
  • Non-Steroidal: adverse e
  • Peptic Ulcer Hemorrhage
  • Peptic Ulcer Hemorrhage: chemically induced
  • Peptic Ulcer Hemorrhage: etiology
  • Platelet Aggregation Inhibitors
  • Platelet Aggregation Inhibitors: administration &
  • Platelet Aggregation Inhibitors: adverse effects
  • Platelet Aggregation Inhibitors: pharmacology
  • Proton Pump Inhibitors
  • Proton Pump Inhibitors: therapeutic use
  • Risk Factors
  • Thromboxanes
  • Thromboxanes: antagonists & inhibitors
  • Ticlopidine
  • Ticlopidine: analogs & derivatives
  • Ticlopidine: pharmacology
  • Ticlopidine: therapeutic use

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Gianfranco NARDULLI

  • Angel LANAS

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free